A large amount of evidence links brain vascular disorders to cognitive impairment and dementia including Alzheimer's disease (AD). It is believed these defects impair neuronal health and function by restricting transport of nutrients and oxygen to neurons. Additional studies indicate that cerebrovascular dysfunction plays important roles in the pathogenesis of neurodegenerative disorders, a theory also supported by data that the risk of AD increases three fold in stroke patients. Crucial to vascular tissue function and repair is the process of angiogenesis, the generation of new blood vessels from pre-existing vasculature. Angiogenesis is promoted by complex mechanisms including endothelial cell sprouting and plays critical roles in neovascularization, the generation of new blood vessels in damaged tissue. Insufficient angiogenesis in AD brains may represent an important pathogenic mechanism affecting repair of vasculature and leading to neuronal dysfunction. There is now evidence that type 2 diabetes (T2D), a disease also associated with vascular abnormalities in the brain, is a risk factor for dementia. Thus, brain vasculature abnormalities observed in both AD and T2D may provide etiological links between the two disorders. Literature shows that the EphB4/ephrinB2 bidirectional signaling promotes angiogenesis and that the cytoplasmic domain of ephrinB2 is required for this function. Additional reports indicate that endothelial cell sprouting is promoted by angiogenic complexes of Raf-1, Rok-?, and vascular endothelial cadherin (VE- cadherin) and that presenilin1 (PS1) plays important roles in the development, maintenance, and integrity of brain vasculature. Recently, we obtained data that EphB4 stimulates angiogenic complexes between Raf-1, Rok-?, and VE-cadherin and increases sprouting of endothelial cells in vitro in a ?-secretase-dependent manner. In addition, we found that PS1/?-secretase mediates the EphB4-induced cleavage of ephrinB2 and stimulates production of cytoplasmic peptide ephrinB2/CTF2 that regulates cell sprouting. Together, our observations suggest that the PS1/?-secretase system regulates angiogenesis via proteolytic processing of ephrinB2 and production of ephrinB2/CTF2. Here we propose to use animal models to ask whether AD and T2D impair brain neovascularization in response to ischemic injury and whether formation of angiogenic complexes during neovascularization is affected by AD and T2D. In addition, we will examine whether angiogenic complexes in AD and T2D human brains differ from those in normal controls. We will also ask whether peptide ephrinB2/CTF2 promotes neovascularization in vivo and whether it acts as a protective factor against AD- and T2D-linked vascular impairments.

Public Health Relevance

Mount Sinai ADRC: Project 3 Yoon) | NARRATIVE Alzheimer disease (AD) brains show severe defects in the vascular system. It is believed these defects impair neuronal health and function because they restrict transport of nutrients and oxygen to neurons. Type 2 diabetes (T2D) is also associated with damage of brain vasculature and interferes with reparative neovascularization. This application asks whether these disorders affect the ability of the brain to repair vascular damage and examines the effects of AD and T2D on mechanisms that promote brain neovascularization and damage repair. Knowledge produced by this work will help to design therapeutic approaches to help healing of the brain.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005138-35
Application #
9716546
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
35
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Gandal, Michael J; Haney, Jillian R; Parikshak, Neelroop N et al. (2018) Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Science 359:693-697
Huckins, L M; Hatzikotoulas, K; Southam, L et al. (2018) Investigation of common, low-frequency and rare genome-wide variation in anorexia nervosa. Mol Psychiatry 23:1169-1180
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Ki?emet-Piska?, Spomenka; Babi? Leko, Mirjana; Blažekovi?, Antonela et al. (2018) Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. CNS Neurosci Ther 24:734-740
Soleimani, Laili; Ravona-Springer, Ramit; Heymann, Anthony et al. (2018) Depression is more strongly associated with cognition in elderly women than men with type 2 diabetes. Int Psychogeriatr :1-5
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Audrain, Mickael; Haure-Mirande, Jean-Vianney; Wang, Minghui et al. (2018) Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Mol Psychiatry :
Boban, Mirta; Babi? Leko, Mirjana; Miški?, Terezija et al. (2018) Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species. J Neurosci Methods :
Zhu, Carolyn W; Grossman, Hillel; Neugroschl, Judith et al. (2018) A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y) 4:609-616

Showing the most recent 10 out of 555 publications